PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C

被引：0
|
作者：
Ideo, G
Giuseppe, S
Attili, A
Chirianni, A
Craxi, A
Di Perri, G
Picciotto, A
Rizzetto, M
Ruggiero, G
Suter, F
Sarracino, M
机构：
[1] Osped S Giuseppe, Dept Hepatol, Milan, Italy
[2] Univ Roma La Sapienza, Dept Gastroenterol, Rome, Italy
[3] Cotugno Hosp, Dept Infectious, Naples, Italy
[4] Univ Palermo, Dept Gastroenterol, Palermo, Italy
[5] Savoia Hosp, Dept Infect Amedeo, Turin, Italy
[6] Hepatitis Diagnosis & Therapy, Genoa, Italy
[7] Molinette Mauriziano Hosp, Dept Gastroenterol & Hepatol, I-10126 Turin, Italy
[8] Univ Naples, Dept Med & Hepatol, Naples, Italy
[9] Spedali Riumti, Dept Infect Dis, Bergamo, Italy
[10] Roche SPA, Monza, Italy
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1630
引用
收藏
页码：570A / 570A
页数：1
相关论文
共 50 条
  • [21] Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC).
    Ferenci, P
    Shiffman, ML
    Fried, MW
    Sulkowski, MS
    Haeussinger, D
    Zarski, JP
    Goncales, F
    Jensen, DM
    Bonino, F
    Dhumeaux, D
    Blotner, S
    Hoffman, J
    Oliveto, J
    HEPATOLOGY, 2001, 34 (04) : 351A - 351A
  • [22] Ribavirin (RBV) dose reduction in patients with HCV genotype 1 infection receiving combination treatment with peginterferon alfa-2a (40kd) (Pegasys®) plus RBV (Copegus®)
    Lee, JS
    Hu, S
    Lopez-Talavera, JC
    Hoffmann-La Roche, F
    HEPATOLOGY, 2004, 40 (04) : 335A - 335A
  • [23] Differences between genotype 1 patients with SVR or relapse after treatment for chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV)
    Zehnter, Elmar
    Mauss, Stefan
    Beoker, Klaus
    Thomas, Lutz
    Racky, Stefan
    Schmidt, Wolfgang
    Ullrich, Rainer
    Sbrijer, Innessa
    Heyne, Renate
    Schober, Andreas
    John, Christine
    Hey, Karl-Heinz
    Bokemeyer, Bernd
    Kallinowski, Birgit
    Moeller, Bernd
    Pape, Stefan
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2007, 132 (04) : A789 - A789
  • [24] The cost-effectiveness of peginterferon alfa-2a (40kd) (PEGASYS) plus ribavirin (COPEGUS) vs. interferon alfa-2b plus ribavirin for chronic hepatitis C (CHC)
    Sullivan, SD
    Green, J
    Patel, KK
    Craxi, A
    Alberti, A
    Giuliani, G
    De Carli, C
    VALUE IN HEALTH, 2003, 6 (03) : 262 - 263
  • [25] Efficacy and Tolerability of Peginterferon Alfa-2a (40KD) (PEG) and Ribavirin (RBV) in Genotype 5 and 6 Patients with Chronic Hepatitis C Under Real Life Conditions
    Hueppe, Dietrich
    Zehnter, Elmar
    Mauss, Stefan
    Kaiser, Stephan
    Schober, Andreas
    Schuchmann, Marcus
    Boeker, Klaus
    Moog, Gero
    Schiffelholz, Willibold
    Pape, Stefan
    Heyne, Renate
    Ackermann, Frank
    Schmidt, Wolfgang
    John, Christine
    Lohmeyer, Juergen
    Hey, Karl-Heinz
    Alshuth, Ulrich
    GASTROENTEROLOGY, 2009, 136 (05) : A839 - A840
  • [26] Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
    Sherman, M.
    Yoshida, E. M.
    Deschenes, M.
    Krajden, M.
    Bain, V. G.
    Peltekian, K.
    Anderson, F.
    Kaita, K.
    Simonyi, S.
    Balshaw, R.
    Lee, S. S.
    GUT, 2006, 55 (11) : 1631 - 1638
  • [27] QoL benefits observed as early as week 2 with peginterferon alfa-2a (40KD) (pegasys) in combination with ribavirin (RBV) versus interferon alfa-2b plus RBV
    Hassanien, TI
    Cooksley, WGE
    Sulkowski, M
    Smith, C
    Marinos, G
    Lai, MY
    Pastore, G
    Trejo-Estrada, R
    Horta, A
    Vale, E
    Wintfeld, NS
    Neary, M
    Green, J
    JOURNAL OF HEPATOLOGY, 2002, 36 : 110 - 110
  • [28] Safety and adherence to peginterferon alfa-2a (40KD) plus ribavirin (RBV) in black Americans with chronic hepatitis C (CHC) HCV genotype 1
    Howell, CD
    Jeffers, LS
    Hu, S
    Lopez-Talavera, JC
    GASTROENTEROLOGY, 2004, 126 (04) : A722 - A723
  • [29] Randomized, controlled, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) and amantadine (AMA) or placebo in patients with chronic hepatitis C genotype 1 infection.
    Ferenci, P
    Formann, E
    Laferl, H
    Gschwantler, M
    Hackl, F
    Brunner, H
    Datz, C
    Stauber, R
    Munda, P
    Gangl, A
    HEPATOLOGY, 2004, 40 (04) : 396A - 396A
  • [30] Peginterferon alfa-2a (40kd) (Pegasys®) plus ribavirin in chronic hepatitis C:: Retreatment of patients who relapsed virologically after 24 weeks of therapy.
    Goncales, F
    Bernstein, DE
    Berg, C
    Sette, H
    Rasenack, J
    Diago, M
    Jensen, DM
    Cooksley, WGE
    Roberts, P
    Ackrill, AM
    HEPATOLOGY, 2002, 36 (04) : 361A - 361A
12345